TABLE 3.

Impact of IBD medications on SARS‐CoV‐2 infections in IBD patients

	OR (95% CI) a
	Symptoms b	Pneumonia	Hospitalisation	Severe COVID‐19 c
Univariable analysis
Ulcerative colitis
TNF antagonists	0.51 (0.28‐0.90)	0.39 (0.20‐0.73)	—	0.34 (0.14‐0.84)
Crohn's disease
TNF antagonists	0.43 (0.24‐0.78)	0.38 (0.20‐0.73)	0.41 (0.21‐0.80)	0.28 (0.10‐0.76)
Salicylates	2.16 (1.25‐3.74)	2.16 (1.20‐3.89)	2.44 (1.32‐4.52)	2.78 (1.21‐6.37)
Multivariable analysis
Ulcerative colitis
TNF antagonists	—	0.44 (0.22‐0.86)	—	—
Crohn's disease
TNF antagonists	—	—	0.46 (0.23‐0.92)	0.31 (0.11‐0.88)
Salicylates	—	—	—	—

^a Only significant results (univariable analysis, P < 0.05) are reported.

^b Any symptoms of COVID‐19.

^c Ventilatory support or death.